Quantitative assessment of quality of life in New Zealand prostate cancer survivors: the effect of androgen deprivation therapy

Justin W L Keogh; C U Krageloh; D Shepherd; C Ryan; Jonathan Masters; S Osborne; Roderick D MacLeod

doi:10.14312/2052-4994.2013-16

Back

Quantitative assessment of quality of life in New Zealand prostate cancer survivors: the effect of androgen deprivation therapy

Journal article

Open access

Peer reviewed

Quantitative assessment of quality of life in New Zealand prostate cancer survivors: the effect of androgen deprivation therapy

Justin W L Keogh, C U Krageloh, D Shepherd, C Ryan, Jonathan Masters, S Osborne and Roderick D MacLeod

Journal of Cancer Research and Therapy, Vol.1(2), pp.105-110

2013

DOI: https://doi.org/10.14312/2052-4994.2013-16

Files and links (1)

pdf

PDF - Published Version (Open Access)494.67 kBDownload View

Published VersionPDF - Published Version (Open Access)CC BY V4.0, Open Access

Abstract

Oncology and Carcinogenesis

cancer survivorship

cancer therapy

hormonal therapy

quality of life

prostrate cancer

Men with prostate cancer experience many challenges to their quality of life (QOL). While some of these challenges reflect the direct effects of the cancer, additional side-effects and symptoms are also associated with common treatments especially androgen deprivation therapy (ADT). While several studies have examined the effects of ADT on the QOL of men with prostate cancer, much of this research is between 10-20 years old and was conducted in North America or Europe. This study therefore examined the effects of ADT on QOL in prostate cancer patients (survivors) in the Southern hemisphere. The registries of two New Zealand based hospitals were sourced to identify men with prostate cancer who were using ADT for at least six months (ADT group, n=205) and those who had never used ADT (non-ADT group, n=143). Participants in both groups were mailed a letter of invitation, the WHOQOL-BREF and three facets of the WHOQOL-OLD QOL questionnaire. Response rates of 41% and 40% were obtained for the ADT and non-ADT groups, respectively. QOL scores were generally similar between the groups, with the exception of physical QOL, which was significantly lower in the ADT group. Such results suggest that cancer clinicians, allied health professionals and cancer researchers should not just concentrate on the physical effect of ADT on their survivors' risk of developing osteoporosis, falls-related fracture and cardio-metabolic syndrome, but also devote time to ensure their survivors' perception of their physical QOL is not compromised.

Details

Title: Quantitative assessment of quality of life in New Zealand prostate cancer survivors: the effect of androgen deprivation therapy
Authors: Justin W L Keogh (Author) - University of the Sunshine Coast - Faculty of Science, Health, Education and Engineering
C U Krageloh (Author) - AUT University, New Zealand
D Shepherd (Author) - AUT University, New Zealand
C Ryan (Author) - AUT University, New Zealand
Jonathan Masters (Author) - Auckland City Hospital, New Zealand
S Osborne (Author) - North Shore Hospital, New Zealand
Roderick D MacLeod (Author) - University of Sydney
Publication details: Journal of Cancer Research and Therapy, Vol.1(2), pp.105-110
Publisher: NobleResearch Publishers
Date published: 2013
DOI: 10.14312/2052-4994.2013-16
ISSN: 2052-4994
Copyright note: Copyright © 2013 Keogh JW, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Organisation Unit: University of the Sunshine Coast, Queensland
Language: English
Record Identifier: 99448940402621
Output Type: Journal article

Metrics

62 File views/ downloads

832 Record Views